OMEGA Diagnostics, the Clackmannanshire-based biotechnology firm, has received the first order for its HIV testing kit from a customer in Zimbabwe.

The medical company focused on allergy, food intolerance and infectious disease said it has received its first purchase order for 20,000 units of its VISITECT CD4 Advanced Disease test, worth £80,000.

The Alva-based firm earlier revealed its first 50,000-test order from Nigeria for its VISITECT CD4 350 test, and it said these recent orders demonstrate there is demand for both versions of the test and it is “confident that demand will increase as the outstanding regulatory processes are completed”.

READ MORE: Omega results delayed to gain clarity on deal talks

Colin King, chief executive of Omega Diagnostics, said: “I am delighted that we have now received our first significant purchase orders for both formats of our CD4 test which illustrates there is a clear demand for our innovative and unique products.

"These tests will have a profoundly positive impact for people living with HIV who currently struggle to access the appropriate healthcare.”

READ MORE: Biotech firm Omega gets £630,000 shares lift

The company last week deferred its results until next month for “further time to gain clarity regarding certain ongoing commercial discussions”.

Omega said earlier that trading is in line with management expectations and it has “also made recent progress in its key areas of growth”.